(Q34522196)

English

A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. (English)

1 reference

Europe PubMed Central

2 August 2017

Cytomegalovirus

0 references

cytomegalovirus retinitis

1 reference

based on heuristic

inferred from title

author name string

Vitravene Study Group

1

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

1 April 2002

1 reference

Europe PubMed Central

2 August 2017

American Journal of Ophthalmology

1 reference

Europe PubMed Central

2 August 2017

133

1 reference

Europe PubMed Central

2 August 2017

4

1 reference

Europe PubMed Central

2 August 2017

467-474

1 reference

Europe PubMed Central

2 August 2017

Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Proof of mechanism of antisense drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Randomisation methods in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Statistical methodology: IX. survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

CMV retinitis in the era of HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Changing trends in cytomegalovirus retinitis with highly active anti-retroviral therapy (HAART)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901327-2

7 January 2021

Identifiers

10.1016/S0002-9394(02)01327-2

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34522196&oldid=1524600396"